搜尋結果
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 3 日前Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for ...
Today's Refinance Rates: June 13, 2024—Rates Dip
Forbes· 18 小時前The rate on a 30-year fixed refinance tumbled today. The average rate on a 30-year fixed ...
Alzheimer’s Disease Drug Donanemab Gets Unanimous Backing From FDA Expert Panel
Forbes· 3 日前The panel concluded that the therapeutic is effective in treating the memory-robbing condition ...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 23 小時前High hopes that psychedelic medicines were finally on the pathway to regulation were dashed ...
FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug
Forbes· 4 日前All of the panel’s 11 members endorsed donanemab—which data from a clinical trial suggests can ...
Patent decision offers new look at weighing of factors for discretionary denial by PTAB
Reuters· 1 日前A current case to watch at the Patent Trial and Appeal Board (PTAB) is Vivendum Product Solutions, Inc. v. Rotolight Ltd ...
Eli Lilly’s Alzheimer’s Drug Donanemab Is Being Considered For FDA Approval—Here’s What To Know
Forbes· 4 日前The Peripheral and Central Nervous System Drugs Advisory Committee will meet on Monday to ...
A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
CNBC· 2 日前Eli Lilly became the most valuable health-care company in the world on the back of its ...
Council Post: Employee Health And Wellness Programs Have Overlooked Brain Health: The Case For ...
Forbes· 23 小時前In the fast-paced world of business, where every decision can make or break a company's ...
US Supreme Court bars 'Trump too small' trademark
Reuters· 14 小時前The U.S. Supreme Court barred on Thursday a federal trademark for the phrase "Trump Too ...